FindTrial
Sign In

Prevalence of Cardiometabolic Syndrome and Its Impact on Major Adverse Cardiovascular Events in Chinese Patients with Rheumatoid Arthritis: Evidence from a 15-Year Real-World Cohort Study Study Protocol

Prevalence of Cardiometabolic Syndrome and Its Impact on Major Adverse Cardiovascular Events in Chinese Patients with Rheumatoid Arthritis: Evidence from a 15-Year Real-World Cohort Study Study Protocol

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500104857
Enrollment
Unknown
Registered
2025-06-24
Start date
2025-07-01
Completion date
Unknown
Last updated
2025-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid arthritis

Interventions

Cardiometabolic Syndrome:None

Sponsors

Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age >= 18 years, both males and females; 2.Fulfilled the 1987 American College of Rheumatology (ACR) or 2010 ACR/European League Against Rheumatism (EULAR) criteria; 3.Minimum follow-up duration of 3 months;

Exclusion criteria

Exclusion criteria: 1.Overlapping with other autoimmune diseases (such as systemic lupus erythematosus, systemic sclerosis, dermatomyositis, primary vasculitis, etc.), or with a history of malignancy, or with serious liver/renal diseases; 2.Pregnant women patients; 3.Patients with a history of CVD (including coronary heart disease, stroke, heart failure, peripheral artery disease, arrhythmia, etc.);

Design outcomes

Primary

MeasureTime frame
Major adverse cardiovascular events;The prevalence of CMS and its components in Chinese RA patients ;—

Countries

China

Contacts

Public ContactDai Lie

Sun Yat-sen Memorial Hospital, Sun Yat-sen University

liedai2004@163.com+86 20 8133 2631

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026